Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.
- NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_assertion description "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.
- NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_assertion evidence source_evidence_literature NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.
- NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_assertion SIO_000772 23441129 NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.
- NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_assertion wasDerivedFrom befree-20150227 NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.
- NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_assertion wasGeneratedBy ECO_0000203 NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.
- befree-20150227 importedOn "2015-02-27" NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.